{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:24:28Z","timestamp":1793741068603,"version":"4.6.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"publisher","award":["2019\/6834"],"award-info":[{"award-number":["2019\/6834"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Redox Biology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.redox.2026.104241","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:38:14Z","timestamp":1780123094000},"page":"104241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9876-5826","authenticated-orcid":false,"given":"Bente Sandvei","family":"Skeie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Richard","family":"Craig-Craven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli Renate","family":"Gr\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Biermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Riemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidsel","family":"Bragstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Sarowar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maziar","family":"Behbahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Sleire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schwarzlm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Goplen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Ingeman","family":"Heggdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.S.","family":"Knisely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Egil","family":"Eide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per \u00d8yvind","family":"Enger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.redox.2026.104241_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.redox.2026.104241_bib2","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","article-title":"An analysis of dose-effect relationship in the radiotherapy of malignant gliomas","volume":"5","author":"Walker","year":"1979","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.redox.2026.104241_bib3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/0360-3016(79)90554-6","article-title":"High dose radiation therapy in the treatment of malignant gliomas: final report","volume":"5","author":"Salazar","year":"1979","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.redox.2026.104241_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23053","article-title":"Modified target delineation and moderately hypofractionated radiotherapy for high-grade glioma: a randomized clinical trial","volume":"8","author":"Zhong","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.redox.2026.104241_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.redox.2026.104241_bib6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: a randomized phase II trial of concurrent Bevacizumab and reirradiation versus Bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.redox.2026.104241_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092511","article-title":"Radioresistance in glioblastoma and the development of radiosensitizers","volume":"12","author":"Ali","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"49","key":"10.1016\/j.redox.2026.104241_bib8","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1038\/onc.2015.60","article-title":"Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion","volume":"34","author":"Sleire","year":"2015","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.redox.2026.104241_bib10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/glia.21113","article-title":"Glutamate and the biology of gliomas","volume":"59","author":"de Groot","year":"2011","journal-title":"Glia"},{"issue":"5","key":"10.1016\/j.redox.2026.104241_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/ars.2011.4391","article-title":"The cystine\/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities","volume":"18","author":"Lewerenz","year":"2013","journal-title":"Antioxidants Redox Signal."},{"issue":"31","key":"10.1016\/j.redox.2026.104241_bib12","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1523\/JNEUROSCI.5258-04.2005","article-title":"Inhibition of cystine uptake disrupts the growth of primary brain tumors","volume":"25","author":"Chung","year":"2005","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.redox.2026.104241_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/0028-3886.128280","article-title":"Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma","volume":"62","author":"Takeuchi","year":"2014","journal-title":"Neurol. India"},{"key":"10.1016\/j.redox.2026.104241_bib14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/1471-2407-9-372","article-title":"Early termination of ISRCTN45828668, a phase 1\/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults","volume":"9","author":"Robe","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.redox.2026.104241_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2026.103915","article-title":"Phase I trial combining sulfasalazine and gamma knife radiosurgery for recurrent glioblastoma","volume":"16","author":"Skeie","year":"2026","journal-title":"MethodsX"},{"key":"10.1016\/j.redox.2026.104241_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103779","article-title":"Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial","volume":"92","author":"Kadife","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.redox.2026.104241_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"issue":"5","key":"10.1016\/j.redox.2026.104241_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-Q","article-title":"The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors","volume":"75","author":"Weitzner","year":"1995","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.redox.2026.104241_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.wneu.2012.03.024","article-title":"Gamma knife surgery versus reoperation for recurrent glioblastoma multiforme","volume":"78","author":"Skeie","year":"2012","journal-title":"World Neurosurg."},{"key":"10.1016\/j.redox.2026.104241_bib20","series-title":"SERVICES USDOHAH","article-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","year":"2017"},{"issue":"1","key":"10.1016\/j.redox.2026.104241_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52279-2","article-title":"11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier","volume":"9","author":"Hotta","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.redox.2026.104241_bib22","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.redox.2026.104241_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/neuonc\/noad228","article-title":"Measure what is measurable: PET RANO 1.0 criteria for interpretation of amino acid PET of diffuse gliomas","volume":"26","author":"Albert","year":"2024","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.redox.2026.104241_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"33","key":"10.1016\/j.redox.2026.104241_bib25","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"Rano 2.0: update to the response assessment in Neuro-Oncology criteria for High- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.redox.2026.104241_bib26","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3174\/ajnr.A8396","article-title":"A neuroradiologist's guide to operationalizing the response assessment in Neuro-Oncology (RANO) criteria version 2.0 for gliomas in adults","volume":"45","author":"Ellingson","year":"2024","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"10.1016\/j.redox.2026.104241_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.redox.2026.104241_bib28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav. Res."},{"issue":"3","key":"10.1016\/j.redox.2026.104241_bib29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaoncol.2015.4833","article-title":"Quality and reporting accuracy of phase 1 drug radiation clinical trials","volume":"2","author":"Kim","year":"2016","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.redox.2026.104241_bib30","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/j.wneu.2014.06.011","article-title":"Increased survival using delayed gamma knife radiosurgery for recurrent high-grade glioma: a feasibility study","volume":"82","author":"Dodoo","year":"2014","journal-title":"World Neurosurg."},{"issue":"5","key":"10.1016\/j.redox.2026.104241_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.redox.2026.104241_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1227\/NEU.0000000000001344","article-title":"Indications and efficacy of Gamma knife stereotactic Radiosurgery for recurrent glioblastoma: 2 decades of institutional experience","volume":"80","author":"Imber","year":"2017","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.redox.2026.104241_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11060-021-03883-8","article-title":"Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study","volume":"155","author":"Bunevicius","year":"2021","journal-title":"J. Neuro Oncol."},{"issue":"5","key":"10.1016\/j.redox.2026.104241_bib34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/nop\/npz017","article-title":"Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival","volume":"6","author":"Chapman","year":"2019","journal-title":"Neuro-Oncol. Pract."},{"issue":"1","key":"10.1016\/j.redox.2026.104241_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12874-021-01454-z","article-title":"Oversampling and replacement strategies in propensity score matching: a critical review focused on small sample size in clinical settings","volume":"21","author":"Bottigliengo","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"issue":"2","key":"10.1016\/j.redox.2026.104241_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amjmed.2019.08.055","article-title":"Propensity score matching: the 'Devil is in the Details' where more may be hidden than you know","volume":"133","author":"Reiffel","year":"2020","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.redox.2026.104241_bib37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.redox.2026.104241_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J. Neurosurg."},{"issue":"8","key":"10.1016\/j.redox.2026.104241_bib39","first-page":"625","article-title":"Revised WHO classification of tumours of the central nervous system:summary of the revision and perspective","volume":"44","author":"Komori","year":"2016","journal-title":"Noshinkeigeka"},{"issue":"1","key":"10.1016\/j.redox.2026.104241_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.redox.2026.104241_bib41","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/ncomms5196","article-title":"Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells","volume":"5","author":"Watkins","year":"2014","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.redox.2026.104241_bib42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1750-3639.2005.tb00118.x","article-title":"Proteases and glioma angiogenesis","volume":"15","author":"Lakka","year":"2005","journal-title":"Brain Pathol."},{"issue":"1","key":"10.1016\/j.redox.2026.104241_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40478-020-01115-0","article-title":"Three-dimensional vascular microenvironment landscape in human glioblastoma","volume":"9","author":"Cribaro","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"3","key":"10.1016\/j.redox.2026.104241_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s004010000180","article-title":"Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme","volume":"100","author":"Liebner","year":"2000","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.redox.2026.104241_bib45","series-title":"Pubchem Compound Summary for CID 6918037: Gadoterate Meglumine Bethesda (MD)","year":"2026"},{"issue":"289","key":"10.1016\/j.redox.2026.104241_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa8103","article-title":"SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma","volume":"7","author":"Robert","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.redox.2026.104241_bib47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/jmri.25221","article-title":"MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T","volume":"44","author":"Bisdas","year":"2016","journal-title":"J. Magn. Reson. Imag."},{"issue":"4","key":"10.1016\/j.redox.2026.104241_bib48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3171\/jns.1990.72.4.0610","article-title":"Quantitative analysis of glutathione in human brain tumors","volume":"72","author":"Kudo","year":"1990","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.redox.2026.104241_bib49","series-title":"Biophysical Reviews","author":"S","year":"2026"},{"issue":"24","key":"10.1016\/j.redox.2026.104241_bib50","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1021\/acschemneuro.3c00717","article-title":"Glutathione depletion and concomitant elevation of susceptibility in patients with Parkinson's disease: state-of-the-art MR spectroscopy and neuropsychological study","volume":"14","author":"Shukla","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"8","key":"10.1016\/j.redox.2026.104241_bib51","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.57.8.1422","article-title":"Brain glutathione levels in patients with epilepsy measured by in vivo (1)H-MRS","volume":"57","author":"Mueller","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.redox.2026.104241_bib52","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/mrm.26532","article-title":"Quantification of glutathione in the human brain by MR spectroscopy at 3 Tesla: Comparison of PRESS and MEGA-PRESS","volume":"78","author":"Sanaei Nezhad","year":"2017","journal-title":"Magn. Reson. Med."},{"issue":"6","key":"10.1016\/j.redox.2026.104241_bib53","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/mrm.21086","article-title":"Detection of an antioxidant profile in the human brain in vivo via double editing with MEGA-PRESS","volume":"56","author":"Terpstra","year":"2006","journal-title":"Magn. Reson. Med."},{"issue":"2","key":"10.1016\/j.redox.2026.104241_bib54","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/jmri.27842","article-title":"Assessment of the precision in measuring glutathione at 3 T with a MEGA-PRESS sequence in primary motor cortex and occipital cortex","volume":"55","author":"Anton","year":"2022","journal-title":"J. Magn. Reson. Imag."},{"issue":"9","key":"10.1016\/j.redox.2026.104241_bib55","article-title":"In vivo brain GSH: MRS methods and clinical applications","volume":"10","author":"Bottino","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"10.1016\/j.redox.2026.104241_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JOP.2016.018937","article-title":"Radiation therapy for glioblastoma: American society of clinical oncology clinical practice guideline endorsement of the American society for radiation oncology guideline","volume":"13","author":"Sulman","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.redox.2026.104241_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.786739","article-title":"The styryl benzoic acid derivative DC10 potentiates radiotherapy by targeting the xCT-Glutathione axis","volume":"12","author":"Sarowar","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.redox.2026.104241_bib58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccell.2017.02.018","article-title":"O(2)(\u22c5-) and H(2)O(2)-Mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate","volume":"31","author":"Schoenfeld","year":"2017","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.redox.2026.104241_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417158","article-title":"Differential H(2)O(2) metabolism among glioblastoma subtypes confers variable responses to pharmacological ascorbate therapy combined with chemoradiation","volume":"24","author":"Zaher","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.redox.2026.104241_bib60","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1158\/1078-0432.CCR-19-0594","article-title":"First-in-Human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma","volume":"25","author":"Allen","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.redox.2026.104241_bib61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1078-0432.CCR-22-3952","article-title":"Magnetic resonance imaging of iron metabolism with T2\u2217 mapping predicts an enhanced clinical response to pharmacologic ascorbate in patients with GBM","volume":"30","author":"Petronek","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2026.104241_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101804","article-title":"Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy","volume":"38","author":"Cushing","year":"2021","journal-title":"Redox Biol."},{"issue":"17","key":"10.1016\/j.redox.2026.104241_bib63","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1001\/jama.292.17.2150","article-title":"Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation","volume":"292","author":"Chen","year":"2004","journal-title":"JAMA"}],"container-title":["Redox Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231726002399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231726002399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:53:02Z","timestamp":1785225182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213231726002399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":62,"alternative-id":["S2213231726002399"],"URL":"https:\/\/doi.org\/10.1016\/j.redox.2026.104241","relation":{},"ISSN":["2213-2317"],"issn-type":[{"value":"2213-2317","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Redox Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.redox.2026.104241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104241"}}